Study guide
5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes
ASCP Hematology Technologist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Hematopoiesis & Cellular Physiology
1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis
2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias
2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias
3 Chapter 3: Hemolytic Anemias & Erythrocytosis
3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification
4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation
4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment
5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms
5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies
6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems
6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia
7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation
7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays
8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics
8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis
9 Chapter 9: Laboratory Operations, Quality Assessment & Safety
9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges
5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes
Key Takeaways Explain This Topic AI
Myelodysplastic Syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, hypercellular bone marrow with paradoxical peripheral cytopenias, morphologic dysplasia across one or more lineages, and a high risk of leukemic transformation to Acute Myeloid Leukemia (AML).
Hallmarks of dysplastic morphology include dyserythropoiesis (ring sideroblasts with ≥5 iron granules covering ≥1/3 of the nuclear circumference on Prussian blue, internuclear bridging, karyorrhexis, PAS-positive normoblasts), dysgranulopoiesis (acquired Pseudo-Pelger-Huët anomaly with hypolobated/pince-nez nuclei, neutrophil hypogranulation), and dysmegakaryocytopoiesis (micromegakaryocytes, multiple separated round pawn-broker nuclei).
The WHO classification categorizes MDS based on lineage dysplasia, blast count, and cytogenetics: MDS-RS requires ≥15% ring sideroblasts (or ≥5% in the presence of an SF3B1 mutation); MDS-EB-1 has 5–9% BM blasts or 2–4% PB blasts, while MDS-EB-2 has 10–19% BM blasts, 5–19% PB blasts, or the presence of Auer rods.
MDS with isolated del(5q) predominantly affects elderly females, presenting with refractory macrocytic anemia, normal or elevated platelet counts, hypolobated micromegakaryocytes, a favorable prognosis, and an exceptional therapeutic response to lenalidomide.
MDS/MPN overlap syndromes exhibit both dysplastic and proliferative features; Chronic Myelomonocytic Leukemia (CMML) requires persistent peripheral blood monocytosis ≥1.0 × 10^9/L (accounting for ≥10% of the white cell differential), absence of the BCR::ABL1 fusion gene, and <20% blasts in blood and marrow.
Last updated: August 2026
Myelodysplastic Syndromes (MDS) & Overlap Syndromes
Myelodysplastic Syndromes (MDS) represent a heterogeneous group of clonal hematopoietic stem cell malignancies characterized by ineffective hematopoiesis , progressive peripheral blood cytopenias , qualitative morphologic abnormalities ( dysplasia ) in one or more hematopoietic cell lineages, and an inherent propensity for clonal evolution and transformation into Acute Myeloid Leukemia (AML) .
In classic MDS, the bone marrow is typically hypercellular (or occasionally normocellular) due to active clonal expansion, yet the peripheral blood demonstrates severe cytopenias (anemia, bicytopenia, or pancytopenia). This apparent paradox is driven by accelerated intramedullary apoptosis of developing erythroid, myeloid, and megakaryocytic precursors within the marrow microenvironment before they can mature and enter the peripheral circulation. CLONAL STEM CELL INITIATION
- (Acquired Somatic Mutations: SF3B1, TET2, ASXL1, TP53, etc.)
- │
- ▼
- INEFFECTIVE HEMATOPOIESIS
- ┌───────────────────────┴───────────────────────┐
- ▼ ▼
- BONE MARROW COMPARTMENT PERIPHERAL BLOOD
- Hypercellular Marrow • Progressive Cytopenias
- Accelerated Intramedullary Apoptosis (Anemia, Neutropenia, Thrombocytopenia)
- Trilineage Morphologic Dysplasia • Circulating Dysplastic Cells
- Accumulation of Myeloblasts • Risk of Leukemic Transformation (AML)
- 1. Molecular Pathophysiology & Clonal Architecture
MDS arises from the sequential acquisition of somatic driver mutations in a multipotent hematopoietic stem cell. These genetic lesions disrupt core cellular pathways:
RNA Splicing Machinery : Mutations in spliceosome complex genes occur in over 50% of MDS patients. S F 3 B 1 SF3B1 SF 3 B 1 (splicing factor 3b subunit 1) is strongly associated with mitochondrial iron handling abnormalities and the formation of ring sideroblasts . Other spliceosome mutations include S R S F 2 SRSF2 SRSF 2 , U 2 A F 1 U2AF1 U 2 A F 1 , and Z R S R 2 ZRSR2 ZRSR 2 .
Epigenetic Regulation & DNA Methylation : Mutations in T E T 2 TET2 TET 2 , D N M T 3 A DNMT3A D NMT 3 A , and I D H 1 / I D H 2 IDH1/IDH2 I DH 1/ I DH 2 alter DNA methylation patterns, while mutations in A S X L 1 ASXL1 A SX L 1 and E Z H 2 EZH2 EZ H 2 disrupt histone modification and chromatin remodeling, suppressing regular hematopoietic differentiation.
Transcription Factors & Signal Transduction : Alterations in R U N X 1 RUNX1 R U NX 1 , G A T A 2 GATA2 G A T A 2 , E T V 6 ETV6 ET V 6 , N R A S NRAS NR A S , and K R A S KRAS K R A S impair maturation programs and confer proliferative advantages.
DNA Damage Response : Inactivating mutations or deletions of T P 53 TP53 TP 53 (chromosome 17p13) are associated with complex cytogenetics, resistance to alkylating agents and hypomethylating therapies, and rapid transformation to secondary AML with dismal overall survival.
2. Morphologic Hallmarks of Trilineage Dysplasia
Definitive diagnosis of MDS requires meticulous microscopic evaluation of well-prepared Wright-Giemsa-stained peripheral blood smears, bone marrow aspirates, and Prussian blue-stained iron preparations. Dysplasia must be unequivocally identified in ≥ 10 % \ge 10\% ≥ 10% of cells within a specific hematopoietic lineage to qualify as dysplastic for classification purposes. TRILINEAGE DYSPLASIA
- │
- ┌────────────────────────────────┼────────────────────────────────┐
- ▼ ▼ ▼
- [ DYSERYTHROPOIESIS ] [ DYSGRANULOPOIESIS ] [ DYSMEGAKARYOCYTOPOIESIS ]
- Ring Sideroblasts (≥5 Fe • Pseudo-Pelger-Huët • Micromegakaryocytes
- granules encircling ≥1/3 (bilobed/hypolobated (dwarf megakaryocytes)
- of nuclear ring) pince-nez nuclei) • Multiple discrete small
- Internuclear Bridging • Hypogranulation / round "pawn-broker" nuclei
- Multinuclearity & Budding Agranular neutrophils • Hypolobated / Mononuclear
- Megaloblastoid Chromatin • Hypersegmentation / megakaryocytes
- PAS-Positive Normoblasts abnormal clefting • Giant agranular platelets
- A. Dyserythropoiesis
Peripheral Blood : Macrocytic or dimorphic erythrocyte population, marked anisopoikilocytosis with prominent oval macrocytes, coarse basophilic stippling, Howell-Jolly bodies, Pappenheimer bodies (siderotic granules), and circulating dysplastic nucleated red blood cells (NRBCs).
Bone Marrow Aspirate :
Nuclear Alterations : Multinuclearity, irregular nuclear contours, nuclear budding, lobulation, karyorrhexis, and internuclear chromatin bridging (thin chromatin strands connecting two distinct erythroblast nuclei).
Cytoplasmic-Nuclear Asynchrony : Megaloblastoid chromatin —fine, sieve-like, open nuclear chromatin persisting alongside advanced, hemoglobinized cytoplasm (resembling Vitamin B 12 B_{12} B 12 /folate deficiency but unresponsive to vitamin supplementation).
Ring Sideroblasts : Visualized on Prussian blue (Perls' acid ferrocyanide) stain as erythroid precursors with ≥ 5 \ge 5 ≥ 5 siderotic iron granules encircling at least one-third ( ≥ 1 / 3 \ge 1/3 ≥ 1/3 ) of the nuclear circumference . These granules represent iron-overloaded mitochondria arranged around the nucleus.
Periodic Acid-Schiff (PAS) Reaction : Normal erythroblasts are completely PAS-negative. In MDS and erythroleukemia, dysplastic normoblasts demonstrate abnormal cytoplasmic glycogen accumulation, manifesting as diffuse cytoplasmic pink-red positivity or coarse, block-like granular PAS staining .
B. Dysgranulopoiesis
Peripheral Blood and Bone Marrow :
Pseudo-Pelger-Huët Anomaly (Acquired Pelger-Huët) : The most widely recognized granulocytic dysplastic feature. Mature neutrophils demonstrate hypolobation , presenting with bilobed nuclei connected by a thin filament ("pince-nez" or spectacle shape) or completely unsegmented, round/oval/peanut-shaped nuclei with heavily condensed, mature chromatin. Unlike the benign, hereditary Pelger-Huët anomaly (where 100% of neutrophils are bilobed with normal cellular function), acquired Pseudo-Pelger-Huët in MDS affects only a subpopulation of neutrophils and is accompanied by functional impairments and other dysplastic features.
Hypogranulation / Agranularity : Mature neutrophils and myelocytes exhibit pale, washed-out, or completely clear-to-pink cytoplasm due to a failure to synthesize secondary (specific) granules (lactoferrin and alkaline phosphatase deficiency).
Abnormal Nuclear Morphology : Ring-shaped nuclei (doughnut nuclei), hypersegmentation ( > 5 >5 > 5 distinct lobes), nuclear clefting, and chromatin clumping anomalies.
Auer Rods : Fused primary azurophilic granules forming needle-like cytoplasmic crystalline structures inside myeloblasts; their presence in MDS automatically categorizes the disease as MDS with excess blasts-2 (MDS-EB-2) regardless of blast percentage.
C. Dysmegakaryocytopoiesis
Peripheral Blood : Circulating giant, agranular, or hypogranular platelets; circulating bare megakaryocyte nuclei or micromegakaryocyte fragments.
Bone Marrow Aspirate & Biopsy :
Micromegakaryocytes (Dwarf Megakaryocytes) : Abnormally small megakaryocytes (roughly the size of a large myelocyte or monocyte, 12 – 30 μ m 12\text{--}30\ \mu\text{m} 12 – 30 μ m in diameter) with a single round or bilobed nucleus.
Multi-Nucleated / Disconnected Nuclei : Megakaryocytes containing multiple discrete, widely separated, small round nuclei arranged in a triangular or cluster pattern ( "pawn-broker" nuclei ).
Mononuclear / Hypolobated Forms : Large megakaryocytes containing a single non-lobated, round or oval nucleus instead of the normal multi-lobated, polyploid structure ( 16 N to 32 N 16\text{N}\text{ to }32\text{N} 16 N to 32 N ).
3. World Health Organization (WHO) Classification of MDS
The WHO classification stratifies MDS according to the number of dysplastic lineages, the percentage of blasts in peripheral blood and bone marrow, the presence of ring sideroblasts, and specific cytogenetic lesions:
MDS Subtype Dysplastic Lineages Peripheral Blood Cytopenias Bone Marrow Blasts Peripheral Blood Blasts Ring Sideroblasts / Cytogenetics
MDS with Single Lineage Dysplasia (MDS-SLD) 1 lineage ( ≥ 10 % \ge 10\% ≥ 10% ) 1 or 2 lineages < 5 % <5\% < 5% < 1 % <1\% < 1% , no Auer rods < 15 % <15\% < 15% (or < 5 % <5\% < 5% if S F 3 B 1 SF3B1 SF 3 B 1 wild-type)
MDS with Multilineage Dysplasia (MDS-MLD) ≥ 2 \ge 2 ≥ 2 lineages ( ≥ 10 % \ge 10\% ≥ 10% ) 1 to 3 lineages < 5 % <5\% < 5% < 1 % <1\% < 1% , no Auer rods < 15 % <15\% < 15% (or < 5 % <5\% < 5% if S F 3 B 1 SF3B1 SF 3 B 1 wild-type)
MDS with Ring Sideroblasts (MDS-RS) 1 lineage (MDS-RS-SLD) or ≥ 2 \ge 2 ≥ 2 lineages (MDS-RS-MLD) 1 to 3 lineages < 5 % <5\% < 5% < 1 % <1\% < 1% , no Auer rods ≥ 15 % \ge 15\% ≥ 15% ring sideroblasts (or ≥ 5 % \ge 5\% ≥ 5% if S F 3 B 1 SF3B1 SF 3 B 1 mutated )
MDS with Excess Blasts-1 (MDS-EB-1) 0 to 3 lineages 1 to 3 lineages 5 – 9 % 5\text{--}9\% 5 – 9% 2 – 4 % 2\text{--}4\% 2 – 4% , no Auer rods Variable
MDS with Excess Blasts-2 (MDS-EB-2) 0 to 3 lineages 1 to 3 lineages 10 – 19 % 10\text{--}19\% 10 – 19% 5 – 19 % 5\text{--}19\% 5 – 19% , OR presence of Auer rods Variable; high risk of rapid transformation to AML
MDS with Isolated del(5q) Megakaryocytic (hypolobated micromegakaryocytes) Refractory macrocytic anemia; normal or elevated platelets < 5 % <5\% < 5% < 1 % <1\% < 1% , no Auer rods Isolated deletion of chromosome 5q [del(5q)]; favorable prognosis MDS BLAST STRATIFICATION
- Peripheral Blood Blasts: <1% 2 - 4% 5 - 19% ≥ 20%
- │ │ │ │
- Bone Marrow Blasts: <5% 5 - 9% 10 - 19% ≥ 20%
- │ │ │ │
- Classification: MDS-SLD / MLD MDS-EB-1 MDS-EB-2 AML
- MDS-RS / del(5q) (or any Auer rods) (Acute Myeloid)
- MDS with Isolated del(5q)
MDS with isolated del(5q) represents a distinct, genetically defined clinicopathologic entity:
Epidemiology : Predominantly affects elderly females (median age ~68 years; female-to-male ratio ~2:1).
Clinical & Laboratory Profile : Severe, refractory macrocytic anemia (MCV often > 105 fL >105\text{ fL} > 105 fL ), normal-to-leukopenic white count, and characteristically normal or elevated platelet count (thrombocytosis) .
Bone Marrow Morphology : Normal-to-increased cellularity with an abundance of pathognomonic small, hypolobated or non-lobated micromegakaryocytes containing single eccentric round nuclei.
Molecular Mechanism & Therapy : Deletion of the critical 5q31-q33 chromosomal band results in haploinsufficiency of the RPS14 gene (causing p53 activation and erythroid arrest) and the microRNA-145/146a genes (upregulating TRAF6/TIRAP and driving megakaryocyte proliferation and thrombocytosis). Lenalidomide binds cereblon ( C R B N CRBN CRBN ) to induce ubiquitination and degradation of casein kinase 1A1 ( C S N K 1 A 1 CSNK1A1 CSN K 1 A 1 ), selectively killing del(5q) clonal cells and producing transfusion independence in over 65 % 65\% 65% of patients.
4. Myelodysplastic / Myeloproliferative Neoplasms (MDS/MPN Overlap Syndromes)
Overlap syndromes exhibit combined clinicopathologic features of both myelodysplasia (ineffective hematopoiesis, cytologic atypia, peripheral cytopenias) and myeloproliferation (autonomous effective overproduction of mature cells, marked leukocytosis or thrombocytosis, organomegaly). MDS/MPN OVERLAP SYNDROMES
- │
- ┌────────────────────────────────┼────────────────────────────────┐
- ▼ ▼ ▼
- [ CMML ] [ aCML ] [ MDS/MPN-RS-T ]
- Persistent Monocytosis • Severe Granulocytic Dysplasia • Refractory Anemia +
- ≥1.0 × 10^9/L (≥10% WBC) with Leukocytosis Thrombocytosis (≥450 × 10^9/L)
- Blasts <20% • BCR::ABL1 Negative • Ring Sideroblasts ≥15%
- BCR::ABL1 Negative • Basophils <2% • SF3B1 + JAK2/CALR/MPL
- Splenomegaly & Dysplasia • SETBP1 / ETNK1 Mutations Co-mutations
- A. Chronic Myelomonocytic Leukemia (CMML)
CMML is the most prevalent MDS/MPN overlap neoplasm. Diagnostic criteria established by the WHO require:
Persistent Peripheral Blood Monocytosis : Absolute monocyte count ≥ 1.0 × 10 9 / L \ge 1.0 \times 10^9/\text{L} ≥ 1.0 × 1 0 9 / L , with monocytes accounting for ≥ 10 % \ge 10\% ≥ 10% of the total leukocyte differential count .
Absence of the B C R : : A B L 1 BCR::ABL1 BCR :: A B L 1 Fusion Gene : Rules out CML presenting with monocytosis.
No Rearrangements of P D G F R A PDGFRA P D GFR A , P D G F R B PDGFRB P D GFRB , F G F R 1 FGFR1 FGFR 1 , or J A K 2 JAK2 J A K 2 .
Blasts < 20 % <20\% < 20% : Total myeloblasts, monoblasts, and promonocytes must comprise < 20 % <20\% < 20% in blood and marrow.
CMML-0 : Blasts < 2 % <2\% < 2% in PB and < 5 % <5\% < 5% in BM.
CMML-1 : Blasts 2 – 4 % 2\text{--}4\% 2 – 4% in PB or 5 – 9 % 5\text{--}9\% 5 – 9% in BM.
CMML-2 : Blasts 5 – 19 % 5\text{--}19\% 5 – 19% in PB, 10 – 19 % 10\text{--}19\% 10 – 19% in BM, or presence of Auer rods.
Genetic Mutations : Recurrent somatic mutations in T E T 2 TET2 TET 2 (~60%) , S R S F 2 SRSF2 SRSF 2 (~50%) , A S X L 1 ASXL1 A SX L 1 (~40%) , and K R A S / N R A S KRAS/NRAS K R A S / NR A S .
B. Atypical Chronic Myeloid Leukemia (aCML), B C R : : A B L 1 BCR::ABL1 BCR :: A B L 1 -Negative
Features : Marked leukocytosis with prominent dysgranulopoiesis (severe pseudo-Pelger-Huët, hypogranulation, abnormal nuclear shapes) and granulocytic precursors (promyelocytes, myelocytes, metamyelocytes) comprising ≥ 10 % \ge 10\% ≥ 10% of total WBCs.
Distinction from Classical CML : Lacks the Philadelphia chromosome / B C R : : A B L 1 BCR::ABL1 BCR :: A B L 1 fusion; basophilia is absent or minimal ( basophils < 2 % <2\% < 2% of WBCs , unlike the prominent basophilia of CML); frequently harbors S E T B P 1 SETBP1 SETBP 1 and E T N K 1 ETNK1 ETN K 1 mutations.
C. MDS/MPN with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
Features : Combines the dysplastic erythroid features of MDS-RS with the proliferative thrombocytosis of Essential Thrombocythemia.
Diagnostic Criteria : Refractory anemia with ≥ 15 % \ge 15\% ≥ 15% ring sideroblasts on marrow Prussian blue stain, sustained platelet count ≥ 450 × 10 9 / L \ge 450 \times 10^9/\text{L} ≥ 450 × 1 0 9 / L , and bone marrow proliferation of large, atypical megakaryocytes.
Molecular Pathogenesis : Characterized by co-occurring mutations: S F 3 B 1 SF3B1 SF 3 B 1 mutation (driving ring sideroblast formation) combined with a J A K 2 JAK2 J A K 2 V617F mutation (or less commonly CALR or MPL , driving megakaryocyte hyperproliferation and thrombocytosis).